Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Buy” by Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have earned an average recommendation of “Buy” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $42.83.

A number of research firms have recently issued reports on DNTH. Cantor Fitzgerald began coverage on Dianthus Therapeutics in a research report on Thursday, June 27th. They set an “overweight” rating on the stock. Wedbush boosted their price objective on Dianthus Therapeutics from $33.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. Raymond James boosted their price target on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a research note on Thursday, April 18th. Jefferies Financial Group boosted their price target on Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, March 22nd. Finally, HC Wainwright initiated coverage on Dianthus Therapeutics in a research note on Thursday, May 16th. They issued a “buy” rating and a $40.00 price target on the stock.

Dianthus Therapeutics Stock Up 1.3 %

Shares of NASDAQ DNTH opened at $28.61 on Friday. The business’s 50 day moving average is $24.49 and its two-hundred day moving average is $22.60. The company has a market cap of $839.70 million, a P/E ratio of -4.91 and a beta of 1.89. Dianthus Therapeutics has a 12 month low of $6.58 and a 12 month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The firm had revenue of $0.87 million during the quarter, compared to analyst estimates of $0.48 million. Sell-side analysts expect that Dianthus Therapeutics will post -2.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Dianthus Therapeutics during the first quarter worth $390,000. RA Capital Management L.P. bought a new position in shares of Dianthus Therapeutics during the first quarter worth about $69,990,000. Janus Henderson Group PLC bought a new position in shares of Dianthus Therapeutics during the first quarter worth about $11,251,000. Bain Capital Life Sciences Investors LLC bought a new position in Dianthus Therapeutics in the first quarter valued at approximately $89,761,000. Finally, StemPoint Capital LP bought a new position in Dianthus Therapeutics in the first quarter valued at approximately $1,304,000. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.